GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gujarat Terce Laboratories Ltd (BOM:524314) » Definitions » Debt-to-EBITDA

Gujarat Terce Laboratories (BOM:524314) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is Gujarat Terce Laboratories Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Gujarat Terce Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.0 Mil. Gujarat Terce Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.0 Mil. Gujarat Terce Laboratories's annualized EBITDA for the quarter that ended in Dec. 2023 was ₹37.1 Mil. Gujarat Terce Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Gujarat Terce Laboratories's Debt-to-EBITDA or its related term are showing as below:

BOM:524314' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.91   Med: 3.85   Max: 21.89
Current: 12.6

During the past 13 years, the highest Debt-to-EBITDA Ratio of Gujarat Terce Laboratories was 21.89. The lowest was -3.91. And the median was 3.85.

BOM:524314's Debt-to-EBITDA is ranked worse than
94.06% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs BOM:524314: 12.60

Gujarat Terce Laboratories Debt-to-EBITDA Historical Data

The historical data trend for Gujarat Terce Laboratories's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gujarat Terce Laboratories Debt-to-EBITDA Chart

Gujarat Terce Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.86 2.79 -2.36 4.92 -3.91

Gujarat Terce Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -12.28 - 1.78 -

Competitive Comparison of Gujarat Terce Laboratories's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Gujarat Terce Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gujarat Terce Laboratories's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gujarat Terce Laboratories's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Gujarat Terce Laboratories's Debt-to-EBITDA falls into.



Gujarat Terce Laboratories Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Gujarat Terce Laboratories's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(58.11 + 14.612) / -18.613
=-3.91

Gujarat Terce Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 37.076
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Gujarat Terce Laboratories  (BOM:524314) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Gujarat Terce Laboratories Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Gujarat Terce Laboratories's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Gujarat Terce Laboratories (BOM:524314) Business Description

Traded in Other Exchanges
N/A
Address
Near Shivalik High-Street,, D/801 & 802,The First,, Behind Keshavbaug Party Plot,, Vastrapur,, Ahmedabad, GJ, IND, 380015
Gujarat Terce Laboratories Ltd is an India company having business in the medical and pharmaceutical preparations. It is engaged in the manufacturing of tablets, capsules, and syrup and injection. It offers branded as well as generic formulations covering different therapeutic areas such as antibiotics, respiratory, nutraceuticals, gastrointestinal, anti-fungal, and many more. Some of the main brands are Acolate, Tynol, DFS, Resplash , Aziter and others.

Gujarat Terce Laboratories (BOM:524314) Headlines

No Headlines